Sei Investments Co. Grows Stake in Sanofi (NASDAQ:SNY)

Sei Investments Co. raised its stake in shares of Sanofi (NASDAQ:SNY) by 8.0% during the fourth quarter, HoldingsChannel reports. The firm owned 644,302 shares of the company’s stock after buying an additional 47,801 shares during the quarter. Sei Investments Co.’s holdings in Sanofi were worth $31,075,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in Sanofi during the fourth quarter worth $135,933,000. Boston Partners lifted its holdings in shares of Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after acquiring an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC lifted its holdings in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock worth $161,103,000 after acquiring an additional 1,705,148 shares during the last quarter. DAVENPORT & Co LLC boosted its stake in shares of Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after purchasing an additional 664,455 shares during the period. Finally, Thrivent Financial for Lutherans grew its holdings in Sanofi by 36.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock valued at $93,774,000 after purchasing an additional 514,542 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on SNY shares. The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price target for the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Stock Performance

Shares of SNY stock opened at $55.45 on Wednesday. The firm has a market cap of $140.72 billion, a price-to-earnings ratio of 22.27, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average is $54.84 and its 200 day moving average is $52.82.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, sell-side analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.